Ina Mathilde Kjær

Ina Mathilde Kjær

Auto-generated profile, based on publicly available information

Ina Mathilde Kjær

Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Reproductive Toxicology
Verified
Journal Article
Closed access
PGPhilippe Grandjean
Philippe Grandjean
CGCiea Grønlund
Ciea Grønlund
IKIna M. Kjær
Ina M. Kjær
TJTina Kold Jensen
Tina Kold Jensen
NSNicolina Sørensen
Nicolina Sørensen
Pal WeihePal Weihe
Pal Weihe

1 December 2017 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
IKIna Mathilde Kjaer
Ina Mathilde Kjaer
TBTroels Bechmann
Troels Bechmann
IBIvan Brandslund
Ivan Brandslund
JMJonna Madsen
Jonna Madsen
Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.

24 May 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IKIna Mathilde Kjær
Ina Mathilde Kjær
SKSøren Kahns
Søren Kahns
STSigne Timm
Signe Timm
RARikke Fredslund Andersen
Rikke Fredslund Andersen
JMJonna Skov Madsen
Jonna Skov Madsen
TBTroels Bechmann
Troels Bechmann
Neoadjuvant treatment of breast cancer is applied to an increasing extent, but treatment response varies and side effects pose a challenge. The vitamin E isoform delta-tocotrienol might enhance the efficacy of chemotherapy and reduce the risk of side effects. The aim of this study was to investigate the clinical effect of delta-tocotrienol combined with standard neoadjuvant treatment and the possible association between detectable circulating tumor DNA (ctDNA) during and after neoadjuvant treatment with pathological treatment response. This open-label, randomized phase II trial included 80 women with newly diagnosed, histologically verified breast cancer randomized to standard neoadjuvant treatment alone or in combination with delta-tocotrienol. There was no difference in the response rate or frequency of serious adverse events between the two arms. We developed a multiplex digital droplet polymerase chain reaction (ddPCR) assay for the detection of ctDNA in breast cancer patients that targets a combination of two methylations specific for breast tissue (LMX1B and ZNF296) and one cancer specific methylation (HOXA9). The sensitivity of the assay increased when the cancer specific marker was combined with the ones specific to breast tissue (p < 0.001). The results did not show any association between ctDNA status and pathological treatment response, neither at midterm nor before surgery.

6 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IKIna Mathilde Kjær
Ina Mathilde Kjær
DODorte Aalund Olsen
Dorte Aalund Olsen
IBIvan Brandslund
Ivan Brandslund
TBTroels Bechmann
Troels Bechmann
EJErik Hugger Jakobsen
Erik Hugger Jakobsen
JMJonna Skov Madsen
Jonna Skov Madsen
Epidermal growth factor receptor (EGFR) and its ligands are involved in cancer pathogenesis. The emerging role of treatments co-targeting the EGFR system in breast cancer has increased the need to identify companion biomarkers. The aim of this study is to investigate whether pretreatment serum levels of EGFR and EGFR ligands in early-stage breast cancer patients might provide prognostic information as a stepping stone for further investigation. The study, which included 311 early-stage breast cancer patients, investigated associations between preoperative serum levels of EGFR and EGFR ligands (epidermal growth factor, heparin-binding epidermal growth factor (HBEGF), amphiregulin, transforming growth factor-α and betacellulin) and survival. Cutoffs were determined using Youden’s method, and overall survival (OS) and invasive disease-free survival (IDFS) were evaluated using Cox regression. Preoperative S-EGFR < 60.3 ng/mL was associated with shorter OS and IDFS in both univariate analyses and when adjusting for standard prognostic factors (p < 0.05). Preoperative S-HBEGF < 21.4 pg/mL was associated with shorter OS in both univariate and multivariate analyses, whereas association with shorter IDFS could only be demonstrated in the univariate analysis. In conclusion, our study demonstrated shorter survival in early-stage breast cancer patients who had low pretreatment levels of either S-EGFR or S-HBEGF.

7 June 2019 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
IKIna Mathilde Kjær
Ina Mathilde Kjær
DODorte Aalund Olsen
Dorte Aalund Olsen
AAAnne Alnor
Anne Alnor
IBIvan Brandslund
Ivan Brandslund
TBTroels Bechmann
Troels Bechmann
JMJonna Madsen
Jonna Madsen
Background: The epidermal growth factor receptor (EGFR) system is involved in cancer pathogenesis and serves as an important target for multiple cancer treatments. EGFR and its ligands epidermal growth factor (EGF), heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC), amphiregulin (AREG) and transforming growth factor α (TGF-α) have potential applications as prognostic or predictive serological biomarkers in cancer. The aim was to establish EGFR and EGFR ligand reference intervals in healthy women. Methods: EGFR and EGFR ligands were measured in serum from 419 healthy women aged 26–78 years. The need for age partitioned reference intervals was evaluated using Lahti’s method. EGFR and EGF were analyzed using ELISA assays, whereas HB-EGF, BTC, AREG and TGF-α were analyzed using the highly sensitive automated single molecule array (Simoa) enabling detection below the lower reference limit for all six biomarkers. Results: Reference intervals for EGFR and the EGFR ligands were determined as the 2.5th and 97.5th percentiles. All six biomarkers were detectable in all serum samples. For EGFR, EGF, HB-EGF and TGF-α, reference intervals were established for women 55 years, whilst common reference intervals were established for AREG and BTC including women aged 26–78 years. Conclusions: Age specific reference intervals were determined for EGFR, EGF, HB-EGF, BTC, AREG and TGF-α.